Status:
UNKNOWN
Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Urinary Tract Infections
Eligibility:
All Genders
18+ years
Brief Summary
The purposes of this study are: 1. To estimate the prevalence of extended spectrum β-lactamase (ESBL) and/or AmpC among Enterobacteriaceae which cause community-onset urinary tract infections (UTIs) ...
Eligibility Criteria
Inclusion
- Adult patients who admitted to the Taipei Veterans General Hospital with the diagnosis of community-onset UTI caused by Enterobacteriaceae will be eligible for inclusion in this study if hospitalization for parental antimicrobial therapy is required
Exclusion
- pregnancy or lactation in women,
- history of serious allergy or intolerance to study drug therapy (patients with a history of mild rash to β-lactams could be enrolled),
- complete obstruction of the urinary tract,
- peri-nephritic or intrarenal abscess, prostatitis, any rapidly progressive disease or terminal illness,
- immuno-compromising illness or immuno suppression therapy, the need for concomitant antimicrobials in addition to study therapy,
- a baseline pathogen resistant to study drug,
- treatment with a systemic antimicrobial agent for \>24 h within 72 h prior to enrolment, or absolute neutrophil count \<1000/mm3.
- Men with a history or physical findings suggestive of acute or chronic prostatitis will also excluded.
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT01138566
Last Update
June 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Vterans General Hospital
Taipei, Taiwan, 11217